secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001193125-24-140591
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca signs Joyo/Medshine licenses for pan-RAS/KRAS; cuts 18% staff, deprioritizes ERAS-007
--------------------------------------------------------------------------------

- In-licensed pan-RAS inhibitor from Joyo for $12.5M upfront + up to $176.5M milestones; lead candidate ERAS-0015.
- In-licensed pan-KRAS inhibitor from Medshine for $10M upfront + up to $160M milestones; lead candidate ERAS-4001.
- Workforce reduction of ~18% primarily in drug discovery; estimated $2.2M charges in Q2 2024.
- Discontinuing internal ERAS-4 pan-KRAS program; deprioritizing ERAS-007 due to insufficient efficacy data and ERAS-801.
- Pipeline focus on naporafenib, ERAS-0015, and ERAS-4001.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312524140591/0001193125-24-140591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312524140591/d832290d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-140591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer